**Abstract**

**Background**—Susceptibility to coeliac disease is strongly associated with particular HLA class II alleles. However, non-HLA genetic factors are likely to be required for the development of the disease. Among candidate genes is the CTLA-4 (cytotoxic T lymphocyte associated) gene located on chromosome 2q33 in humans, which encodes a cell surface molecule providing a negative signal for T cell activation.

**Aims**—To investigate CTLA-4 exon 1 polymorphism (position 49 A/G) in patients with coeliac disease.

**Patients**—101 patients with coeliac disease and 130 healthy controls.

**Methods**—Allele specific hybridisation and restriction enzyme digestion of polymerase chain reaction amplified genomic DNA.

**Results**—The A allele of the CTLA-4 position 49 polymorphism was found on 82.2% of chromosomes in patients with coeliac disease compared with 65.8% in controls (p<0.0001), mostly in the homozygous form (68.3% in patients versus 47.7% in controls; odds ratio (OR) 2.36, 95% confidence interval (CI) 1.37 to 4.06, p=0.002). Four patients only had the G/G genotype compared with 21 controls (OR 0.21, CI 10.07 to 0.64, p=0.002). These differences were maintained when subjects were stratified according to the HLA class II phenotype, in particular when patients and controls were matched for the presence of the predisposing HLA DQB1*02 (DQ2) allele or HLA-DQA1*0501/DQB1*02 heterodimer.

**Conclusion**—The CTLA-4 gene polymorphism is associated with predisposition to coeliac disease. Whether it directly contributes to disease susceptibility or represents a marker for a locus in linkage disequilibrium with CTLA-4 needs further investigation.

(Gut 1998;43:187–189)

Keywords: coeliac disease; CTLA-4 gene; genetic susceptibility; HLA association

Coeliac disease is a gluten sensitive enteropathy characterised by small bowel mucosal atrophy. A T cell mediated immune response to some immunodominant wheat gliadin peptides may play a crucial role in the disease. Ingestion of gluten containing cereals probably induces immunologically mediated intestinal injury in genetically susceptible individuals. A significant part of the genetic component maps to the HLA class II region of the major histocompatibility complex (MHC). More than 90% of patients with coeliac disease express a DQßβ heterodimer encoded by the DQβ1*02 (DQ2) and DQA1*0501 alleles in the cis position in DR3 patients, or in the trans position in DR7/11 heterozygous patients. However, some individuals develop a typical disease in the absence of known predisposing alleles.

Previous family studies have suggested that other non-HLA loci might be stronger determinants of inheritance of coeliac disease than the HLA locus itself. A genome wide screening approach using polymorphic microsatellite markers in affected sibpairs from western counties of Ireland has recently proposed several candidate regions that might contribute to coeliac disease. However, only one of the newly mapped intervals has been replicated in a linkage analysis study of 28 coeliac disease families, confirming that several independent studies are required for confirmation of linkage results in complex multigenic diseases. This is further complicated by heterogeneities in different populations and/or ethnic groups.

Another approach involves analysis of candidate genes that are directly related to autoimmune disorders, using the case control association method. CTLA-4 on chromosome 2q33 is a likely candidate gene for autoimmune diseases because of its role in controlling the T cell proliferative response. The CTLA-4 gene encodes a T lymphocyte surface molecule whose binding to the B7 molecule on antigen presenting cells delivers a negative signal to the T cell and can mediate its apoptosis. CTLA-4 deficient mice develop a lymphoproliferative disease with multiorgan lymphocytic infiltration and tissue destruction. Association of insulin dependent diabetes mellitus (IDDM) and Graves’ disease with a point mutation in exon 1 of CTLA-4 (position 49 A/G) leading to a Thr/Ala substitution in the leader peptide has recently been described in several different populations by combined association and linkage studies.

The functional importance of the CTLA-4 molecule has prompted us to examine its contribution to predisposition to coeliac disease in unrelated individuals.

**Patients and methods**

One hundred and one French Caucasian patients with coeliac disease (54 females, 47 males) were recruited from the Departments of Pediatrics, Hôpital Necker-Enfants Malades,
Table 1  Polymorphism at CTLA-4 exon 1 position 49 in patients with coeliac disease and controls

<table>
<thead>
<tr>
<th>Nucleotide at position 49</th>
<th>Coeliac disease (n=101)</th>
<th>Controls (n=130)</th>
<th>Odds ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenotype frequencies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A positive (Thr)</td>
<td>97 (96.0)</td>
<td>109 (83.8)</td>
<td>4.67 (1.54-14.09)*</td>
</tr>
<tr>
<td>G positive (Ala)</td>
<td>32 (31.7)</td>
<td>68 (52.3)</td>
<td>0.42 (0.24-0.72)*</td>
</tr>
<tr>
<td>Genotype frequencies‡</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AA (Thr/Thr)</td>
<td>69 (68.3)</td>
<td>62 (47.7)</td>
<td>2.36 (1.37-4.06)‡</td>
</tr>
<tr>
<td>AG (Thr/Ala)</td>
<td>28 (27.7)</td>
<td>47 (36.2)</td>
<td></td>
</tr>
<tr>
<td>GG (Ala/Ala)</td>
<td>4 (4.0)</td>
<td>21 (16.2)</td>
<td>0.21 (0.07-0.64)‡</td>
</tr>
<tr>
<td>Allele frequencies§</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A (Thr)</td>
<td>166 (82.2)</td>
<td>171 (65.8)</td>
<td></td>
</tr>
<tr>
<td>G (Ala)</td>
<td>36 (17.8)</td>
<td>89 (34.2)</td>
<td></td>
</tr>
</tbody>
</table>

Results are expressed as number (%).

* p values of odds ratios defined by Fisher's exact test (A phenotype), or \( \chi^2 \) test (1 DF) using a 2x2 contingency table (G phenotype); p=0.0027 for both.
† \( \chi^2 \) test of heterogeneity (2 DF) using a 2x2 contingency table; p=0.0013.
‡ \( \chi^2 \) test of heterogeneity (2 DF) using a 3x2 contingency table; p=0.0027 for both.
§ \( \chi^2 \) test of heterogeneity (1 DF) using a 2x2 contingency table; p<0.0001.

Hôpital Robert Debré, and Hôpital Trousseau, Paris, and have been described in detail elsewhere.7-11 All were diagnosed during childhood from 1981 to 1995 and fulfilled ESPGAN criteria. The control group consisted of 130 French Caucasian blood donor volunteers.

HLA class II typing was performed using sequence specific oligotyping after genomic DNA amplification of the DRB1, DQB1, and DQA1 loci by the polymerase chain reaction (PCR).22 The CTLA-4 exon 1 position 49 A/G polymorphism was typed using standard PCR allele specific dot blot hybridisation as previously described,11 with PCR primers (forward 5'-GCTCTACTTCTCGAAAGACCT-3' and reverse 5'-GCTCTACTTCCTGAAGACCT-3'; 35 cycles of 30 seconds at 94°C for denaturing, 30 seconds at 50°C for annealing, and 60 seconds at 72°C for extension) and detection oligonucleotides (5'-AACCTGGCTGCGAGGAGGAC-3' and 5'-AACCTGGCTACGGAGGACC-3'). The presence of the G allele of CTLA-4 position 49 polymorphism was confirmed by digestion of the PCR product with the restriction endonuclease BbvI and visualisation of the fragments on 2.5% agarose gels stained with ethidium bromide.

Allele and phenotype frequencies were determined for patient and control groups. Odds ratios (OR) were calculated according to Woolf's formula, and the p value was defined by \( \chi^2 \) analysis using a 2x2 or 2x3 contingency table, or Fisher's exact test where appropriate. A value of p<0.05 was considered significant.

Results

The frequency of G allele positive individuals was significantly increased in patients with coeliac disease relative to controls (96% and 83.8% respectively; OR 4.67, 95% confidence interval (CI) 1.54 to 14.09, p=0.002; table 1). The A allele frequency was 82.2% in patients with coeliac disease compared with 65.8% in controls (p=0.0001). This difference reflected a significant increased frequency of the A/A genotype in patients (68.3% versus 47.7% in controls; OR 2.36, CI 1.37 to 4.06, p=0.002). Conversely, the G/G genotype was observed in only 4% of patients with coeliac disease compared with 16.2% of controls (OR 0.21, CI 0.07 to 0.64, p=0.002).

To investigate a possible interaction between the CTLA-4 and HLA genes, stratification of the patients was done according to their DR-DQ phenotype (table 2). The distribution of A and G alleles was first compared in DRB1*03-DQB1*02-DQA1*0501 positive or negative patients and matched controls. The increased frequency of the A/A genotype and the decreased frequency of the G/G genotype were still observed in all coeliac disease patient subgroups relative to controls, whatever the HLA phenotype (2x3 \( \chi^2 \) contingency table analysis, p=0.005 and p=0.04 respectively). In the same manner, patients and controls stratified for the presence of the HLA-DQB1*02 allele or for the presence of the cis or trans encoded DQA1*0501/DQB1*02 heterodimer were compared. The vast majority of patients with coeliac disease expressed the A allele of the CTLA-4 position 49 polymorphism in both groups (95.7% and 95.2% respectively, versus 81.6% and 80.8% in controls; 2x3 \( \chi^2 \) contingency table analysis, p<0.002). In particular, the four patients with coeliac disease showing the unfrequent G/G genotype all expressed the predisposing DQA1*0501/DQB1*02 heterodimer, encoded either in cis (one DR3/4 patient), in trans (one DR7/11 patient), or in both positions (two DR3/7 patients).

Discussion

Although the HLA component of coeliac disease susceptibility is well characterised and relatively simple, little is known about the role of genes other than HLA. One or more genes at HLA unlinked loci also predispose to coeliac disease and are probably stronger determinants of disease susceptibility than HLA, as indirectly shown by the high disease concordance rate in monozygotic twins (71%) compared with only 30% in HLA identical siblings.21 The non-secretor state, using red cell Lewis (Le) blood group phenotype to infer secretor status, has been reported to be significantly associated with coeliac disease, suggesting that genes on chromosome 19 may directly or indirectly participate in conferring disease susceptibility. A recent genome wide study,16 has proposed a number of candidate regions on chromosomes 6p23 (distinct from HLA), 6p12, 3q27,
CTLA-4 gene and predisposition to coeliac disease

189

5q33.3, 7q31.3, 11p11, 15q26, 19p13.3, 19q13.1, 19q13.4, and 22cen for the location of a non-HLA linked susceptibility gene. However, in another linkage study, IL-1R1 and IL-1R2, and there was no significant evidence for linkage of coeliac disease to these markers, except for D15S642 on chromosome 15q26.

Our results show an association of the A allele of CTLA-4 position 49 polymorphism with predisposition to coeliac disease. The frequency of this allele was not more increased in patients expressing the classic predisposing HLA alleles or allelic combinations, which suggests that the effects of the HLA and CTLA-4 loci are independent. Because of the well known clinical heterogeneity in coeliac disease, in particular according to the age at disease onset and the autoantibody status of the patients, it might be interesting to try to relate genotype to disease presentation. In the present study however, all the patients were diagnosed during childhood. Furthermore, most of them were diagnosed before antiendomysium antibodies were routinely used as a screening test, so that it was not possible to analyse the relation between this parameter and the genetic marker studied.

Whether CTLA-4 contributes to coeliac disease susceptibility by itself, or is a marker for another locus in linkage disequilibrium with CTLA-4, is unclear. Furthermore, the aetiological mutations on the CTLA-4 gene may not have been found. The dimorphism at position 49 of exon 1, leading to Thr/Ala substitution, has not been found. The dimorphism located 5.3 kb upstream and the A/G polymorphism associated with Graves' disease in Caucasians, is in strong linkage disequilibrium with CTLA-4, as well as with HLA-DR and -DQ.

1 D Jillali-Saiah was supported by the Fondation pour la Recherche Médicale.